Free Trial
ASX:PAR

Paradigm Biopharmaceuticals (PAR) Stock Price, News & Analysis

Paradigm Biopharmaceuticals logo

About Paradigm Biopharmaceuticals Stock (ASX:PAR)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1.81 million shs
Average Volume
N/A
Market Capitalization
$196.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Receive PAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paradigm Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PAR Stock News Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
Paradigm Biopharmaceuticals Ltd. (PBIGF) Receives a Buy from Bell Potter
See More Headlines

PAR Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), Mesoblast (MESO), CytoDyn (CYDY), Bubs Australia (BUB), Blue Energy (BLU) and BHP Group (BHP).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
Computer Hardware
Current Symbol
ASX:PAR
CIK
N/A
Fax
N/A
Employees
1,480
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-58,650,000.00
Net Margins
-89,138.58%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$79,224.00
Price / Cash Flow
6.44
Book Value
A$0.08 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$196.66 million
Optionable
Not Optionable
Beta
0.94
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (ASX:PAR) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners